Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient Response From the Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials

Main Article Content

James Del Rosso
H. Chih-ho Hong
Leon Kircik
Melinda Gooderham
Mark Lebwohl
Kim Papp
Linda Stein Gold
Adelaide Hebert
Melissa Seal
David Krupa
David Chu
Patrick Burnett
David Berk
Robert Higham


roflumilast cream, psoriasis, Psoriasis Area and Severity Index, PASI, individual response, safety, tolerability, Investigator Global Assessment


1. Lebwohl MG, et al. JAMA. 2022;328:1073-1084.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>